

Further regarding Company Presentation

Perth, Australia; 11 September 2024: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) refers to its announcement released on ASX on 30 August 2024 titled “Company Presentation” (“Presentation”).

As previously announced, Orthocell confirms it is targeting a 20% global market share for each of its products Remplir™ and Striate+™ as part of its global market expansion strategy. As set out in the Presentation, the addressable nerve reconstruction market is estimated to exceed US\$3.5 billion per annum and the addressable global dental barrier membrane market is estimated to be US\$732 million (for collectively just the AU, NZ, US, EU/UK, SGP, CAN, BRZ, JAP and THA markets).

To the extent the statements on slides 23 and 29 of the Presentation identifying revenue figures representing 20% of the relevant addressable market could be considered prospective financial information, the Company retracts those two statements. The Company advises that it does not have a reasonable basis for providing prospective financial information at this stage and investors should therefore disregard those two statements.

Release authorised by the Chair of Orthocell Ltd, John Van Der Wielen.

For more information, please contact:

General & Investor enquiries

Paul Anderson

Orthocell Limited

Managing Director

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

Media enquiries

Haley Chartres

HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

ACN 118 879 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include Collagen Medical Device platform which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US, Canada, Australia, New Zealand, UK and Europe and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian and New Zealand markets. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd



Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only

